Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. (Nasdaq: CUE) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts and focused on developing injectable biologics that selectively engage disease-specific T cells. News about Cue Biopharma often centers on its Immuno-STAT platform, clinical data from its CUE-100 series programs, and progress in autoimmune disease and oncology.
Investors and followers of CUE stock can use this page to review company press releases and third-party coverage related to Cue Biopharma’s pipeline. Typical updates include clinical trial readouts for CUE-101 in HPV16+ head and neck cancer and CUE-102 in WT1-expressing tumors, as well as developments around CUE-401, the company’s lead autoimmune asset designed to promote regulatory T cell–mediated tolerance.
News flow also highlights Cue Biopharma’s strategic collaborations and corporate milestones. Examples include agreements with Boehringer Ingelheim for CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases, and a collaboration and license agreement with ImmunoScape to advance a Seed-and-Boost cell therapy approach for solid tumors using the CUE-100 series. Financial updates, such as quarterly results, collaboration revenue disclosures and public equity offerings under the company’s shelf registration statement, are also common topics.
By following this CUE news feed, readers can track regulatory interactions, investigator-sponsored trials, leadership transitions, licensing deals and financing activities that may influence Cue Biopharma’s development trajectory. Bookmark this page to quickly access the latest headlines and historical announcements related to Cue Biopharma and its Immuno-STAT-based biologics.
On December 15, 2021, Cue Biopharma announced the appointment of Patricia Nasshorn as Chief Business Officer. Her extensive experience in business development and partnerships is expected to bolster the company’s growth, particularly amid promising data from the ongoing CUE-101 trial, which highlights the potential of their interleukin 2-based CUE-100 series in immuno-oncology. CEO Daniel Passeri expressed optimism about Nasshorn's contributions to Cue Biopharma’s strategic initiatives and future collaborations.
Cue Biopharma (Nasdaq: CUE) announced its participation in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2021, from 11:40 a.m. to 12:10 p.m. EST. The session will feature a clinical update on CUE-101, its lead program, evaluating its effectiveness as a monotherapy and in combination with KEYTRUDA® for patients with HPV+ recurrent/metastatic head and neck cancer. The company will also discuss developments in its CUE-100 series pipeline. Interested parties can access the live and archived webcast on their website.
Cue Biopharma (CUE) announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The company will feature a pre-recorded fireside chat, available on its website starting November 22, 2021, at 10:00 a.m. EST. Cue Biopharma is focused on developing a novel class of injectable biologics that engage T cells, aiming to transform treatments for cancer and autoimmune diseases. The archived recording will be accessible for 90 days post-event.
Cue Biopharma (CUE) presented promising interim data for CUE-101, a monotherapy targeting HPV+ head and neck cancer, at SITC 2021. CUE-101 showed durable partial responses and favorable tolerability in its Phase 1 trial, with doses administered exceeding 190. Additionally, early results indicated potential activity when combined with pembrolizumab. CUE-102 demonstrated the ability to activate WT1-specific T cells, supporting its advancement towards clinical trials. The company plans to file for Investigational New Drug status for CUE-102 in Q1 2022, enhancing its development pipeline.
On November 10, 2021, Cue Biopharma (Nasdaq: CUE) announced its participation in two upcoming virtual fireside chats. The first will occur at the Stifel Healthcare Conference from November 15-17, while the second will take place at the Jefferies London Healthcare Conference from November 16-19. Cue Biopharma will update participants on its lead clinical program, CUE-101, and its related CUE-100 series pipeline, addressing treatments for HPV+ recurrent/metastatic head and neck cancer. Webcasts of these discussions will be available on the company's website.
Cue Biopharma announced promising findings from a study published in the Journal of Clinical Investigation, revealing that its Immuno-STAT™ Biologics can activate and expand anti-viral cytotoxic T cells targeting HIV and CMV. The study indicates potential for treating chronic viral infections without ex vivo manipulation of T cells, addressing a critical barrier in HIV treatment. Ongoing Phase 1 trials of CUE-101 also show positive outcomes in cancer therapy. The modularity of the Immuno-STAT platform suggests versatility in treating various infectious diseases.
Summary not available.
On September 28, 2021, Cue Biopharma announced a publication in Scientific Reports detailing their innovative peptide-HLA-based platform technologies for selective immune modulation. The research emphasizes the potential of their Immuno-STAT and Neo-STAT platforms to develop targeted therapeutics for cancer, infectious, and autoimmune diseases. Key findings highlight their ability to safely activate T cells, enhancing therapeutic efficacy while minimizing adverse effects. The lead candidate, CUE-101, has shown promising results in clinical trials for HPV+ recurrent head and neck cancer.
Cue Biopharma announced the issuance of two new U.S. patents (Nos. 11,117,945 and 11,104,712) that enhance its intellectual property portfolio. These patents cover CUE-101, Cue's lead clinical candidate for treating HPV16-related cancers, currently in a Phase 1b trial. The drug has shown a 40% clinical benefit rate in early patients. The second patent focuses on the combination of CUE-101 with KEYTRUDA for similar cancer treatments. These developments bolster the company's position in immunotherapy and support its ongoing clinical trials.
Cue Biopharma, a clinical-stage biopharmaceutical company, will participate in two virtual fireside chats at major healthcare conferences. The first is Baird's 2021 Global Healthcare Conference from September 14-15, where they will discuss their lead clinical program, CUE-101, targeting HPV+ recurrent/metastatic head and neck cancer. The second event is the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 20-23. Presentations will highlight the latest updates and pipeline progress. Webcasts will be available for conference participants and archived for later viewing.